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A B S T R A C T
Background: Fracture risk is increased in individuals with type 2 diabetes (T2D). The pathophysiological me-
chanisms accentuating fracture risk in T2D are convoluted, incorporating factors such as hyperglycaemia, in-
sulinopenia, and antidiabetic drugs. The objectives of this study were to assess whether diﬀerent insulin regi-
mens, metformin and rosiglitazone inﬂuence bone metabolism. We explored if the concentration of metformin
and rosiglitazone in blood or improved glycaemic control altered bone turnover.
Methods: Two-year clinical trial designed to investigate eﬀects of antidiabetic treatment in 371 T2D patients.
Participants were randomized to short or long-acting human insulin (non-blinded) and then further randomized
to metformin+placebo, rosiglitazone+ placebo, metformin+ rosiglitazone or placebo+ placebo (blinded).
Fasting bone turnover markers (BTM) representing bone resorption (CTX) and formation (PINP) including
HbA1c were measured at baseline and after 3, 12 and 24months. Trough steady-state plasma concentrations of
metformin and rosiglitazone were measured after 3, 6 and 9months of treatment. Associations between treat-
ments and BTMs during the follow-up of the trial were analysed in mixed-eﬀects models that included adjust-
ments for age, gender, BMI, renal function and repeated measures of HbA1c.
Results: BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP
increasing 28.5% and 23.0% (all: p < 0.001), respectively. Allocation of insulin regimens was not associated
with diﬀerent levels of BTMs. Metformin and metformin+ rosiglitazone but not rosiglitazone alone were as-
sociated with lower bone formation (PINP). Neither metformin nor rosiglitazone plasma concentrations was
associated with BTMs. HbA1c was inversely associated with CTX but not P1NP.
Conclusions: The choice of insulin treatment is not inﬂuencing BTMs, metformin treatment may decrease BTMs,
and improvement of glycaemic control may inﬂuence bone resorption activity.
1. Introduction
Despite higher body mass and bone mineral density (BMD) in pa-
tients with type 2 diabetes (T2D), hip fracture risk is increased by
1.4–1.7 with risks increasing to 2.7 in studies with at least ten years of
follow up [1,2]. Several factors might inﬂuence fracture risk in T2D
including higher prevalence of falls, renal disease, and anti-diabetic
medication [3]. Insulin resistance, hyperinsulinaemia and hypergly-
caemia are dominant characteristics of T2D, but limited information is
available regarding their eﬀects on bone metabolism. Most clinical
studies investigating biochemical markers of bone turnover (BTM)
measured in peripheral blood or bone remodelling assessed in bone
biopsies have reported lower bone turnover in T2D [4,5]. In vitro,
hyperglycaemia promotes adipogenesis rather than osteogenesis, im-
pairs osteoblast growth, increases osteoblast apoptosis [6–8] and in-
hibits osteoclastogenesis [9]. Insulin and insulin receptor signalling
stimulate osteoblast proliferation and diﬀerentiation in human osteo-
blast-like cells [10], whereas insulin resistance in bone impairs bone
formation and resorption in mice [11]. The sensitivity of osteoblasts
and osteoclasts to insulin or hyperglycaemia from individuals with T2D
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is undetermined.
Alterations in bone metabolism due to anti-diabetic medication may
inﬂuence bone metabolism both directly, e.g. by insulin promoting
bone formation, and indirectly by improvement of glycaemic control
[12,13]. Correction of hypoinsulinaemia in type 1 diabetes increases
bone mass [14], indicating bone anabolic eﬀects of insulin or normal-
isation of bone remodelling due to normoglycaemia, correction of
acidosis or increased body weight, but similar investigations in patients
with T2D are absent. Rather, insulin treatment is associated with in-
creased fracture risk [13], possibly explained by an increased occur-
rence of hypoglycaemia, falls or renal complications. Preclinical in-
vestigations have revealed that the antidiabetic drug metformin has
osteogenic eﬀects on bone marrow progenitor cells [15], promotes os-
teoblast activity and reduces osteoclastogenesis [16], possibly due to
activation of the AMPK and subsequently Runx2 [17], and attenuates
the inhibitory eﬀects of hyperglycaemia on osteoblast activity [18],
whereas clinical studies have reported that metformin reduces or has no
eﬀect on fracture risk [13]. Pharmacogenetic investigations show that
plasma metformin concentration varies considerably between in-
dividuals [19], possibly contributing to the divergence in previous re-
sults. Thiazolidinediones (TZDs) including rosiglitazone activates per-
oxisome proliferator-activated receptor gamma (PPARg), which
stimulates the diﬀerentiation of mesenchymal stem cells into adipo-
cytes rather than osteoblasts [20]. In eﬀect, while improving insulin
sensitivity [21], rosiglitazone increases bone resorption [12], which has
been shown to increase fracture risk by 2.1 (95% CI 1.61–2.51) in
women but not men [22]. The concentration of rosiglitazone diﬀers
between individuals due to genetic variations in CYP2C8*3 [23], but it
is unknown if these variations are associated with modiﬁcations in bone
metabolism.
This study investigates the eﬀects of diﬀerent insulin regimens and
additional treatment with metformin, rosiglitazone or placebo as well
as glucose control on bone metabolism in patients with T2D.
Furthermore, we explore if the concentration of rosiglitazone and
metformin aﬀect bone turnover.
2. Materials and methods
2.1. Subjects
The South Danish Diabetes Study (SDDS) has previously been de-
scribed in detail [24]. In brief, SDDS was a 2-year long investigator-
driven randomized controlled multicentre trial that aimed to elucidate
if insulin aspart at meal times was superior to long acting NPH insulin
at night in controlling glucose levels and whether the addition of
metformin or rosiglitazone or both to one of the two insulin regimens
improved glucose control. Candidates for SDDS were men and women
with T2D who were 30–70 years old, had a BMI>25 kg/m2, a fasting
C-peptide>300 pmol/l and HbA1C>7%. Doses used to treat T2D
needed to be stabile for at least 3 months. Those with congestive heart
failure, impaired renal function, intolerance to metformin, or any
treatment with a TZD<30 days were excluded. Individuals treated
with antiresorptive drugs such as bisphosphonates and systemic corti-
costeroids were excluded from all analyses.
2.2. Protocol
This study was carried out at ﬁve public hospital centres in
Denmark. In all, 450 persons were included in the study, and 371 of
these were eligible for the trial. The intention-to-treat population
comprised 369 individuals as two were withdrawn prior to the ﬁrst
eﬃcacy evaluation. After informed consent, the participants were
randomly assigned to one of eight diﬀerent treatment groups in a fac-
torial design. First, all participants were randomized to either insulin
aspart at mealtime or NPH insulin at bedtime. Secondly, the partici-
pants in these groups were randomly assigned to either
metformin+ placebo, rosiglitazone+placebo, metformin+ rosiglita-
zone, or placebo+ placebo. Metformin, rosiglitazone and placebo
treatments were blinded to the participants and investigators. Previous
anti-diabetic treatment was stopped. Those assigned to insulin NPH
who were insulin naïve started on 12 IU whereas participants on insulin
treatment at initiation of the trial were started on 50% of their total
daily dose at bedtime. Subsequently, the dose was increased until
fasting blood glucose (FBG) and HbA1C were less than 5.5mmol/l and
6.5%, respectively. Insulin naïve and participants treated with insulin at
initiation of the trial who were allocated to insulin aspart were started
on either 4 IU or 50% of their previous total daily dose of insulin evenly
divided in three at mealtime, respectively. Doses of insulin aspart were
increased until postprandial glucose levels and HbA1C were< 7.5
mmol/l and 6.5%, respectively. Insulin aspart and NHP doses were
titrated rigorously for the ﬁrst three months of the trial, but doses were
only increased if there were no limiting cases of hypoglycaemia. Oral
treatments were initiated at the start of the study. Those allocated to
metformin/placebo treatment were started on 500mg tablets twice
daily, with doses being increased to 1000mg twice daily after 4 weeks
whereas those on rosiglitazone/placebo treatment started on tablets of
4mg once daily, and the dose was increased to 8mg once daily after
8 weeks.
Randomization was performed using a computer that generated
random blocks of 8 participants. While the type of insulin was not
blinded, assignment to oral treatment was double-blinded. The local
ethics committee approved the trial (M-2417-02), which was registered
with clinicaltrials.gov as NCT00121966.
2.3. Biochemical tests
Patients monitored capillary blood glucose daily (One Touch Ultra,
LifeScan). At baseline, 3, 6, 9, 12 months and at 24months, blood
samples from the participants were drawn between 8 am and 10 am in
the fasting state and stored at −80 °C until analysis. Measurements for
HbA1c was included for 0, 3, 12 and 24months. BTMs were measured
in unthawed samples collected at 0, 3, 12 and 24months by use of a
fully automated immunoassay system (iSYS, Immunodiagnostic
Systems Ltd., Boldon, England) in a single run with the same batch of
the reagents/assay. Serum Procollagen type I amino-terminal propep-
tide (PINP) and C-telopeptide of type I collagen (CTX) were measured
using the chemiluminescence method. The intra- and inter-assay coef-
ﬁcients of variation (CV) for PINP were 3% and 5–8%, respectively
(normal range in men and women 27.7–127.6 μg/l), and the intra- and
inter-assay CV for CTX were < 5% and 7–10%, respectively (men
115–748 ng/l, premenopausal women 112–738 ng/l, postmenopausal
women 142–1351 ng/l). The plasma concentrations of metformin and
rosiglitazone were measured in unthawed samples collected at 3, 6 and
9months using validated high-performance liquid chromatography
methods as previously described [19,25]. The lower limit of detection
for metformin and rosiglitazone were 20 ng/ml and 0.25 ng/ml, and the
lower limit of quantiﬁcation for each drug was 30 ng/ml and 1 ng/ml,
respectively [19,23]. BTMs and concentrations of medications were
measured at dissimilar time points, as unthawed samples were un-
available for measurement of BTMs at 6 and 9months.
2.4. Statistics
A total of three patients were excluded due to concomitant intake of
bisphosphonates. Basic demographics are presented as median with
interquartile range (IQR). Glomerular ﬁltration rate (eGFR) was esti-
mated using the MDRD equation (using plasma creatinine, gender and
age). Both CTX and PINP were transformed using natural logarithm to
ensure a Gaussian distribution. To examine the changes in CTX and
PINP we used mixed-eﬀect modelling with restricted maximum like-
lihood as previously described [19,23]. Both unadjusted (not adjusted
for any variables) and adjusted (adjusted for BMI and eGFR, selected a
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priori) models were run. To investigate possible covariates inﬂuencing
CTX and PINP concentrations, age, gender, type of insulin (aspart vs.
NPH), type of oral antidiabetic drug (OAD) and HbA1c were tested in
both the unadjusted and adjusted models. To assess whether metformin
and rosiglitazone plasma levels correlated with CTX or PINP con-
centrations after three months, we performed linear regression analysis.
Two models were run; one unadjusted and one model adjusted for BMI
and eGFR (selected a priori). Post hoc analyses of all models were
performed by including age and gender in the adjusted models. This led
to no changes in the obtained conclusions. To assess the inﬂuence in-
sulin regimen we ran a model including only BTM and insulin regimen.
The SDDS trial was designed and powered to investigate eﬀects on
glucose control, therefore, the results presented here should be con-
sidered exploratory. A two-sided p-value below 0.05 was considered
statistically signiﬁcant.
3. Results
A total of 371 patients (38% women) with a median age of 57 years
(IQR: 51.5–63.0 years) were included and randomized in the South
Danish Diabetes Study. Demographic data and patient characteristics at
baseline, 3, 12 and 24months are shown in Table 1. There were no
diﬀerences in age, gender, body weight, and HbA1c or diabetes dura-
tion between groups [24].
The number of participants in each treatment group included: 46 on
NPH insulin and placebo, 45 on NPH insulin and metformin, 46 on NPH
insulin and rosiglitazone, and 46 on NPH insulin and both metformin
and rosiglitazone with another 48 on insulin aspart and placebo, 45 on
insulin aspart and metformin, 47 on insulin aspart and rosiglitazone
and 48 on insulin aspart and both metformin and rosiglitazone [24].
During the trial, HbA1c decreased from 8.4 (7.6–9.3) to 7.1 (6.4–8.1) %
(Table 1).
3.1. Changes in BTMs during the trial
The fold change in plasma levels of both CTX and PINP during the
study is shown in Fig. 1, and median levels are shown in Table 1.
Plasma concentration of CTX initially dropped to 78% (CI 95%:
72–84%) of the initial concentration three months after inclusion to the
study, followed by a marked increase of 125% of the baseline value (CI
95%: 116–134%) 12months after inclusion and 128% (CI 95%:
119–137%) after 24months. Plasma concentrations of PINP were un-
changed three months after inclusion, followed by 115% of the baseline
value (CI 95%: 110–119%) increase 12months after inclusion and
116% (CI 95%: 112–121%) 24months after inclusion.
3.2. Insulin treatment
The fold change of CTX and P1NP in those treated with insulin as-
part or NPH insulin during the study is shown in Fig. 2. Neither CTX nor
P1NP levels diﬀered between insulin regimens (p=0.38 and p=0.29
in unadjusted models respectively).
3.3. CTX
In both the unadjusted and the adjusted model CTX was statistically
signiﬁcantly reduced at 3months and increased at 12 and 24months.
Beta values from the full model with included covariates including re-
peated measures of HbA1c and corresponding conﬁdence intervals are
shown in Table 2. BMI and HbA1c were inversely correlated with CTX
concentrations at 24months while eGFR had no eﬀect. Men had 15%
(95% CI: 2–24%, p=0.03) lower CTX concentrations than women in
this study. Age, type of insulin or OAD regimen had no statistically
signiﬁcant eﬀect on CTX concentrations. Changes in CTX after 3, 12 and
24months according to treatment with placebo, oral antidiabetic drugs
or combinations are presented in Table 2 and in Supplementary mate-
rial (as Fig. 2).
3.4. PINP
In both adjusted and unadjusted analysis, PINP levels were in-
creased at 12 and 24months after study inclusion while no diﬀerence
was observed at 3months. Beta values from the full model with all
statistically signiﬁcant covariates with corresponding conﬁdence in-
tervals are shown in Table 2. In contrast to CTX, BMI was positively
correlated with PINP at 24months while HbA1c had no inﬂuence on
PINP concentrations. Interestingly, among patients randomized to
metformin alone PINP concentrations were 13% lower (CI 95%:
3–22%) while patients randomized to metformin and rosiglitazone had
21% (CI 95%: 12–29%) reduced concentrations of PINP. There was no
statistically signiﬁcant diﬀerence on PINP among patients randomized
to metformin or patients randomized to metformin and rosiglitazone.
Age, gender and type of insulin had no statistically signiﬁcant eﬀect on
PINP plasma concentrations. Changes in P1NP after 3, 12 and
24months according to treatment with placebo, oral antidiabetic drugs
or combinations are presented in Table 2 and in Supplementary mate-
rial (as Fig. 2).
3.5. Correlations between bone turnover markers and drug concentrations
To test whether metformin or rosiglitazone could aﬀect CTX or
P1NP directly, we performed regression analyses. The median plasma
concentration of metformin was 628 ng/ml (IQR: 384–915 ng/ml,
n=148) and the median plasma concentration of rosiglitazone was 18
(IQR: 8–33 ng/ml, n=176). Two models were run; one unadjusted
model and one model adjusted for eGFR and BMI. The plasma con-
centration of metformin or rosiglitazone did not correlate with CTX or
P1NP (Supplementary material. Table 1).
4. Discussion
Following a minor decline in CTX but not PINP, corresponding in
time to the insulin titration period, both BTMs increased in the study
population and remained signiﬁcantly higher by the end of the study.
While allocation of insulin regimen had no eﬀect on bone turnover,
treatment with an OAD but not the plasma concentration of the OAD
was associated with lower bone formation. Furthermore, as Hb1Ac
declined during the trial and was associated with the level of the bone
resorption marker, improved glycaemic control during the trial may
contribute to an increase in bone turnover after 24months.
Despite evidence of bone anabolic eﬀects of insulin in cells and
rodents, the eﬀect of treatment with insulin on bone turnover in
Table 1
Clinical characteristics and BTMs of 371 patients during the South Danish
Diabetes Study.
Inclusion 3months 12months 24months
HbA1c (%) 8.4 (7.6–9.3) 7.6 (6.9–8.4) 7.2 (6.6–7.9) 7.1 (6.4–8.1)⁎
BMI (kg/m2) 34.6
(31.4–39.3)
34.9
(31.5–39.2)
35.2
(31.8–39.6)
35.4
(31.9–39.7)
eGFR+ (ml/
min/
1.73m2)
76 (67–85) 75 (66–85) 76 (67–86) 75 (65–85)
CTX (ng/l) 140 (90–230) 110 (70–180) 180
(110–290)
180
(120−300)
PINP (μg/l) 27.1
(22.0–36.7)
27.0
(21.1–34.3)
31.6
(24.7–42.9)
33.2
(25.3–43.4)
Data are shown as medians with IQR (25th–75th percentiles).
+eGFR=186 ∗ ((serum creatinine concentration/88.4)^(−1.154)) ∗ (age ^
(−0.203)) ∗ 0.742 (if female).
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individuals with T2D is unknown. At least in theory, the eﬀect of insulin
could depend on the method of exposure to the drug as in the case of
parathyroid hormone (PTH), which is bone catabolic in cases of chronic
hypersecretion, such as primary hyperparathyroidism, whereas exo-
genous administration once daily of PTH is bone anabolic [26]. How-
ever, our data showed no diﬀerence in eﬀects of short and long acting
insulin on bone metabolism. Importantly, these results do not exclude
diﬀerences in fracture risk between diﬀerent insulin regimens. Indeed,
those on insulin aspart experienced more cases of hypoglycaemia as
previously reported [24], which may increase the risk of falls and
subsequently fractures [27]. There were not enough fractures in this
study to provide any meaningful analysis of correlations with either
drug use or BTMs.
Based on available preclinical data, metformin was expected to in-
crease bone formation and reduce bone resorption [15,17,28]. By
contrast, we observed lower level bone formation without concomitant
reduction in bone resorption in those on metformin treatment, and
there was no association between plasma metformin concentrations and
BTMs, not favouring a bone anabolic eﬀect of metformin in humans
with T2D. These results are partly in agreement with the ADOPT trial, a
double-blinded trial designed to compare the antidiabetic eﬀects of
rosiglitazone, glimepiride and metformin in individuals with T2D,
which showed lower levels of CTX and PINP after one year in those
treated with metformin [29]. The ADOPT trial was designed to in-
vestigate glycaemic control using monotherapy [30]; therefore, the
discrepancies in the results of the ADOPT and our trial could be ex-
plained by additional insulin therapy. In addition, reductions in Hb1Ac
were numerically larger in the SDDS than the ADOPT trials, which may
explain why lower levels of both BTMs were observed in the ADOPT
trial [24,29]. Although comparisons of the outcomes of clinical trials
and register-based studies are challenging and should be interpreted
cautiously, our study are to some degree in concert with register-based
studies showing either neutral or slightly beneﬁcial eﬀects of metformin
on bone mass and fracture risk [31].
The eﬀect of TZDs including rosiglitazone on bone metabolism has
been investigated in several studies. Uncoupling of bone remodelling
Fig. 1. Fold change in plasma levels of BTMs after 3, 12
and 24months compared to baseline.
Fig. 1. Plasma levels of CTX decrease intermediately at
three months followed by increase in CTX concentrations
after 12 and 24months. PINP was increased 12 and
24months after inclusion.
PINP: Serum Procollagen type I amino-terminal propep-
tide, CTX: C-telopeptide of type I collagen. Outside values
are excluded for clarity. Boxes depict median (IQR) with
ranges, and those marked with a ⁎indicate a statistically
signiﬁcant change compared to baseline values with a
p < 0.001.
Fig. 2. Changes in plasma levels of BTMs after 3, 12 and
24months compared to baseline in those treated with in-
sulin aspart or insulin NPH.
Fig. 2. Plasma levels of CTX and P1NP are similar in those
treated with insulin aspart and NPH insulin after 3, 12 and
24months.
PINP: Serum Procollagen type I amino-terminal propep-
tide, CTX: C-telopeptide of type I collagen. Outside values
are excluded for clarity. Boxes depict median (IQR) with
ranges.
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with increases in bone resorption but not formation was observed
during treatment with rosiglitazone in a double-blinded, placebo-con-
trolled clinical trial speciﬁcally designed to assess the eﬀect of the in-
vestigational drug on bone metabolism in non-diabetic, post-meno-
pausal women [32], in line with the ADOPT study which revealed
increased bone resorption but not formation in women treated with
rosiglitazone [29]. Additionally, compared to placebo, rosiglitazone
reduced markers of bone formation in postmenopausal diabetic women
[33] and formation but not resorption markers in postmenopausal non-
diabetic women [34]. We did not observe independent eﬀects of ro-
siglitazone on bone resorption or formation, but the combination of
rosiglitazone and metformin was associated with a reduction in bone
formation. These results indicate that concomitant treatment with in-
sulin and metformin could inﬂuence the eﬀects of rosiglitazone on bone
metabolism, further supporting that rosiglitazone inhibits bone forma-
tion. The insigniﬁcant diﬀerences in the eﬀects of rosiglitazone on
P1NP may also be explained by lower power in our investigation. Thus,
we observed a 10% reduction in P1NP in those on rosiglitazone, which
is similar to previous reports of−13% in postmenopausal women over
14 weeks [34] and −4% in women and −13% in men over 12months
in the ADOPT trial [29].
Demonstration of independent eﬀects of insulin or metformin on
bone metabolism in humans including patients with T2D is challenging.
Assessment of bone remodelling by use of dynamic histomorphometry
in bone biopsies collected before and after treatment with either of
these drugs in single-arm trials or in comparison with placebo in pa-
tients with T2D is cumbersome and likely to be inﬂuenced by the in-
dependent eﬀects of alterations in glucose levels on bone turnover.
Uptake of metformin was recently shown not to occur in bone, but this
does not preclude independent eﬀects on bone metabolism [35]. While
assessment of eﬀects of metformin on bone remodelling is feasible in
healthy subjects, enduring insulin therapy in non-diabetics for research
purposes is inconceivable. Exposure to temporary increased levels of
insulin during a hyperinsulinaemic, euglycaemic clamps (HEC) has no
imminent eﬀect on BTMs [36–38], whereas reductions in bone re-
sorption markers were observed during HECs of extended duration (4
rather than 2 h) or hyperinsulinaemic, hypoglycaemic clamps (p-glu-
cose reduced to 2.5mmol/l) [36,38]. Taken together, current clinical
data do not support clinically relevant eﬀects on bone metabolism of
insulin or metformin in individuals with T2D.
Prospective investigations of BTMs in patients with T2D are in
shortage. Among 27 individuals with T2D followed for 5 years, an in-
crease in CTX was observed in women but not men, whereas osteo-
calcin, a bone formation marker, remained at the same level [39].
Despite an initial drop in CTX, possibly explained by changes in medical
therapy causing transient hyperglycaemia, increases in both PINP and
CTX were observed in our study. As hyperglycaemia impairs both os-
teoblast and osteoclast activity, improved glycaemic control may have
contributed to the increase in CTX. While increased bone resorption can
be interpreted as an increase in fracture risk, these changes in CTX
during intensiﬁed antidiabetic treatment may also reﬂect a normal-
isation of bone remodelling. The latter interpretation is supported by
Danish reference intervals [40] showing that levels of BTMs were in the
lower part of the normal range at initiation of the trial and within the
normal range by end of the trial. Since bone formation and HbA1c were
unrelated, our data indicate that improved glycaemic control primarily
modiﬁes bone resorption. Bone formation and resorption are generally
coupled, and future investigations are needed to conﬁrm if lowering of
glucose levels causes alterations in bone resorption and not formation.
PINP increased in our investigation, and we cannot exclude the possi-
bility that changes in both PINP and CTX levels were inﬂuenced by
factors such as improved nutrition and increased physical activity.
Importantly, SDDS was designed to investigate the eﬀects of com-
binations of antidiabetic pharmaceuticals on glucose control in in-
dividuals with T2D, and the results presented here are therefore ex-
ploratory rather than primary outcomes. Furthermore, we assessed
bone turnover using biochemical markers, which, although known to
relate to bone remodelling [41], cannot provide insight into treatment
eﬀects on cortical and trabecular bone remodelling. The T2D skeletal
phenotype has not been completely characterized [42] but is con-
sidered to be a state of low bone turnover [3]. Collection of bone
biopsies in this investigation could have provided information on the
skeletal phenotype and eﬀects of antidiabetic treatments on bone re-
sorption and formation, which may have been overlooked by mea-
surement of BTMs. The conclusions drawn here need conﬁrmation in
trials that encompass sampling of information on bone mass and
structure as well as bone remodelling. We were unable to evaluate the
eﬀects of insulin on bone turnover, because all participants were
treated with insulin. Future investigations may deliver information on
eﬀects of insulin on bone remodelling in T2D, preferably including
individuals with T2D with hypo- and hyperinsulinaemia. Furthermore,
the liver clears PINP, indicating that liver disease such as steatosis may
have increased PINP levels. Assessment of other biochemical markers of
bone formation and resorption such as osteocalcin and tartrate-resistant
acid phosphatase, respectively, may have provided further information
on the relationship between antidiabetic treatment and bone remodel-
ling as these markers may reﬂect somewhat more speciﬁc eﬀects on
osteoblasts and osteoclasts. Bone metabolism is inﬂuenced by sex
steroid hormones such as testosterone, which is lower in individuals
Table 2
Longitudinal analyses of changes of the bone turnover markers C-telopeptide of
type I collagen (CTX) and Procollagen type I amino-terminal propeptide (PINP)
at 3, 12 and 24months using mixed-eﬀect modelling with restricted maximum
likelihood (Adjusted models§). Overall eﬀects of listed variables including re-
peated measures of HbA1c on BTM presented.
Bone turnover
marker
Variable Beta 95% CI P
CTX Baseline 1.00 Reference –
3months 0.78 0.71–0.84 < 0.001
12months 1.23 1.13–1.33 < 0.001
24months 1.26 1.16–1.37 < 0.001
eGFR+ 1.00 1.00–1.00 0.61
BMI+ 0.98 0.97–0.99 0.002
Age+ 1.01 1.00–1.01 0.17
HbA1c+ 0.96 0.93–0.99 0.03
Insulin aspart 1.00 Reference –
Insulin NPH 0.97 0.85–1.10 0.60
Female 1.00 Reference –
Male 0.83 0.72–0.96 0.01
No oral antidiabetic drug 1.00 Reference –
Metformin 0.91 0.76–1.10 0.33
Metformin and
rosiglitazone
0.98 0.81–1.17 0.80
Rosiglitazone 1.08 0.90–1.30 0.41
PINP Baseline 1.00 Reference –
3months 1.00 0.96–1.05 0.90
12months 1.15 1.10–1.20 < 0.001
24months 1.16 1.11–1.22 < 0.001
eGFR+ 1.00 1.00–1.00 0.07
BMI+ 1.01 1.001–1.01 0.03
Age+ 1.01 1.002–1.01 0.008
HbA1c+ 1.00 0.98–1.02 0.91
Insulin aspart 1.00 Reference –
Insulin NPH 0.94 0.88–1.02 0.12
Female 1.00 Reference –
Male 0.95 0.88–1.03 0.19
No oral antidiabetic drug 1.00 Reference –
Metformin 0.87 0.78–0.97 0.01
Metformin and
rosiglitazone
0.79 0.71–0.88 < 0.001
Rosiglitazone 0.90 0.81–1.01 0.07
CTX: C-telopeptide of type I collagen, PINP Serum Procollagen type I amino-
terminal propeptide. HbA1c: Haemoglobin A1c. BMI: Body mass index. §Models
adjusted for all listed variables. +All beta-values for continuous variables in this
table are shown as an increase of BTM with the increase of one unit of the
variable (e.g. one year or 1 kg/m2).
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with comorbidities commonly observed in patients with T2D, including
hypertension and obesity [43]. Sex hormones were not measured in this
investigation but may have inﬂuenced the eﬀects of anti-diabetic drugs
on bone metabolism.
The strengths of this study are mainly the opportunity to investigate
the eﬀects on bone turnover of diﬀerent antidiabetic treatment com-
binations including diﬀerent insulin regimens. We also measured
plasma levels of both metformin and rosiglitazone, allowing us to assess
if the eﬀects were dependent on the concentration of these drugs in
blood, which has not been reported before. Furthermore, all the parti-
cipants were recruited within a geographically small area, seen at
public hospitals, and did not have ﬁnancial incitements to participate in
the trial.
In conclusion, short- or long-acting human insulin treatments are
not causing diﬀerent levels of BTMs, and metformin treatment did not
increase bone formation, in patients with fairly well controlled T2D.
Additionally, rosiglitazone was not associated with increased bone re-
sorption, possibly explained by simultaneous insulin treatment.
Furthermore, our study shows that improved glycaemic control is as-
sociated with higher bone resorption, possibly portraying normalization
rather than an abnormal increase in bone resorption. Further clinical
trials investigating the eﬀects of improved glycaemic control on bone
remodelling including other biochemical markers of bone turnover are
needed to conﬁrm if lowering of glucose levels solely changes bone
resorption and not formation.
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